Volume changes in Alzheimer's disease and mild cognitive impairment: cognitive associations
Volume changes in Alzheimer's disease and mild cognitive impairment: cognitive associations
复制标题
DOI：
10.1007/s00330-009-1581-5
复制
发表时间：
2010-03-01
影响因子：
5.9
通讯作者：
Fox, Nick C.
中科院分区：
文献类型：
--
作者：
Evans, Matthew C.;Barnes, Josephine;Fox, Nick C.
评估阿尔茨海默病（AD）、轻度认知障碍（MCI）和对照受试者的全脑和脑室容积的MRI衍生变化与认知评分变化之间的关系。来自阿尔茨海默病神经影像学倡议（ADNI）队列的231例MCI和99例AD受试者，基线和12个月随访时进行T1加权容积MRI。UP用于导出体积变化。计算同期简易精神状态检查量表（MMSE）、阿尔茨海默病评估量表（ADAS）-cog和trails测试的变化，结果显示，不同受试者组的脑萎缩率和脑室扩大率不同（p < 0.0005），MCI和AD与MMSE变化相关。在MCI患者中，这两项指标还与ADAS-cog和trails-B相关，在AD患者中，心室扩张与ADAS-cog相关。与保持稳定的MCI受试者相比，在随访12个月内进展为AD的MCI受试者的脑萎缩（p < 0.0005）和心室扩张率（p = 0.001）更高。在12个月内进展为AD的MCI受试者的萎缩率与AD受试者相似。患者组和健康对照组的全脑萎缩率和脑室扩大不同，并跟踪疾病进展和心理下降，证明其作为生物标志物的相关性。
To assess the relationship between MRI-derived changes in whole-brain and ventricular volume with change in cognitive scores in Alzheimer's disease (AD), mild cognitive impairment (MCI) and control subjects.In total 131 control, 231 MCI and 99 AD subjects from the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort with T1-weighted volumetric MRIs from baseline and 12-month follow-up were used to derive volume changes. Mini mental state examination (MMSE), Alzheimer's disease assessment scale (ADAS)-cog and trails test changes were calculated over the same period.Brain atrophy rates and ventricular enlargement differed between subject groups (p < 0.0005) and in MCI and AD were associated with MMSE changes. Both measures were additionally associated with ADAS-cog and trails-B in MCI patients, and ventricular expansion was associated with ADAS-cog in AD patients. Brain atrophy (p < 0.0005) and ventricular expansion rates (p = 0.001) were higher in MCI subjects who progressed to AD within 12 months of follow-up compared with MCI subjects who remained stable. MCI subjects who progressed to AD within 12 months had similar atrophy rates to AD subjects.Whole-brain atrophy rates and ventricular enlargement differed between patient groups and healthy controls, and tracked disease progression and psychological decline, demonstrating their relevance as biomarkers.